Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?

Current Urology Reports

Volumn 16, Issue 9, 2015, Pages

  Mischinger, Johannes ^a   Comperat, Eva ^b   Schwentner, Christian ^a   Stenzl, Arnulf ^a   Gakis, Georgios ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Bladder cancer; Checkpoint inhibitor; Escape mechanism; PD 1; PD L1; Prostate cancer

Indexed keywords

BCG VACCINE; CELL SURFACE PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

APOPTOSIS; AUTOIMMUNITY; BLADDER CANCER; CANCER CELL; CANCER INFILTRATION; CELL CYCLE CHECKPOINT; CYTOKINE PRODUCTION; CYTOTOXICITY; HEALTH CARE COST; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MONONUCLEAR CELL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STANDARDIZATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; UROGENITAL TRACT TUMOR; ANIMAL; MALE; METABOLISM; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTIGENS, CD274; APOPTOSIS; HUMANS; INFLAMMATION; MALE; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 84938591692     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-015-0532-8     Document Type: Review

References (48)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–592. doi:10.1093/annonc/mdl498.
2. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349(4):366–81.
3. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248:171–83.
4. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860.
5. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res. 2002;89:213.
6. O’Brien PM, Saveria Campo M. Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res. 2002;88:103.
7. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry. 1998;63:854–65.
8. Gakis G. The role of inflammation in bladder cancer. Adv Exp Med Biol. 2014;816:183–96. A comprehensive book chapter which outlines the current status on the role of inflammation during bladder carcinogenesis and progression.
9. Yamanishi Y et al. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A. 2002;99:10025–30.
10. Hudson JD et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999;190:1375–82.
11. Center MM et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012. doi:10.1016/j.eururo.2012.02.054.
12. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23.
13. Baker LH, Mebust WK, Chin TD, et al. The relationship of herpesvirus to carcinoma of the prostate. J Urol. 1981;125:370.
14. Sutcliffe S, Giovannucci E, Gaydos CA, et al. Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2007;16:1573–80.
15. Herbert JT, Birkhoff JD, Feorino PM, et al. Herpes simplex virus type 2 and cancer of the prostate. J Urol. 1976;116:611.
16. Stark JR, Judson G, Alderete JF, et al. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians’ Health Study. J Natl Cancer Inst. 2009;101(20):1406–11.
17. Grinstein S, Preciado MV, Gattuso P, et al. Demonstration of Epstein- Barr virus in carcinomas of various sites. Cancer Res. 2002;62:4876.
18. Krieger JN, Nyberg Jr L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282(3):236–7.
19. Stimac G, Reljic A, Spajic B, Dimanovski J. Aggressiveness of inflammation in histological prostatitis—correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy. Scott Med J. 2009;54(3):8–12.
20. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999;84(9):976–81.
21. Jiang J, Li J, Yunxia Z, et al. The role of prostatitis in prostate cancer: meta-analysis. PLoS One. 2013;8(12):e85179. doi:10.1371/journal.pone.0085179. eCollection 2013.
22. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology. 2000;56(5):828–32.
23. Robert-Koch-Institut: Krebs in Deutschland 2009/2010, Zentrum für Krebsregisterdaten GEKID, 9. Ausgabe 2013
24. Babjuk M, Oosterlinck W, Sylvester R. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Actas Urol Esp. 2012;36(7):389–402.
25. Stenzl A, Hennenlotter J, Schilling D. Can we still afford bladder cancer? Curr Opin Urol. 2008;18(5):488–92.
26. Abdollah F, Gandaglia G, Thuret R. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013;37(3):219–25.
27. Gakis G, Todenhöfer T, Stenzl A. The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer. Curr Opin Urol. 2011;21(5):428–33.
28. Kawai K, Miyazaki J, Joraku A. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 2013;104(1):22–7.
29. Trikha M, Corringham R, Klein B. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9(13):4653–65.
30. Gakis G, Todenhöfer T, Renninger M, et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int. 2011;108(11):1800–5. The first externally validated inflammation-based prognostic risk model for cancer-specific survival after radical cystectomy.
31. Hwang IS, Yu HS, et al. Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer. Jpn J Clin Oncol. 2012;42(10):955–60.
32. Ajili F, Kourda N, Darouiche A. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy. Ultrastruct Pathol. 2013;37(1):56–61.
33. Edin S, Wikberg ML, Dahlin AM, et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One. 2012;7(10):e47045.
34. Liu W, O’Donnell MA, Chen X, et al. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol Immunother. 2009;58(10):1647–55.
35. Wang YH, Cao YW, Yang XC, et al. Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance. Asian Pac J Cancer Prev. 2014;15(3):1321–6.
36. Zhang D, Zhang G, Hayden MS, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science. 2004;303:1522–6.
37. Song J, Abraham SN. TLR-mediated immune responses in the urinary tract. Curr Opin Microbiol. 2008;11:66–73.
38. Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005;65:5009–14.
39. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.
40. Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64:1140–5.
41. Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109:1499–505.
42. He L, Zhang G, He Y, et al. Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma. Anticancer Res. 2005;25(5):3309–13.
43. Nakanishi J, Wada Y, Matsumoto K, et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2007;56(8):1173–82.
44. Bellmunt J, Mullane SA, Werner L, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015;26:812–7.
45. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847–56.
46. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol. 2015;33C:23–35.
47. Reiss KA, Forde PM, Brahmer JR. Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy. 2014;6(4):459–75.
48. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62. This review describes the scientific rationale for the use of PD-L1 inhibitors in metastatic bladder cancer.